Senekjian H O, Lee C S, Kuo T H, Au D S, Krothapalli R
Eur J Rheumatol Inflamm. 1983;6(2):155-62.
The absorption and disposition of ibuprofen was investigated in seven hemodialyzed uremic patients. Ibuprofen (400 mg) was orally administered to each patient 1 hr or 4 hr prior to hemodialysis. Uremic patients appeared to absorb ibuprofen at a slower rate as compared to normal subjects. The hemodialysis systems used in this study yielded a mean extraction efficiency of 16.7% for ibuprofen, with a mean dialysis plasma clearance of 22.7 ml/min. The drug recovery resulting from hemodialysis represented a small fraction of the ingested dose of ibuprofen (less than 4%). The half-life of ibuprofen (1.3-1.9 hr) was not significantly altered by hemodialysis. Observations of extraction efficiency, drug recovery and half-life during dialysis suggested nondialyzability of ibuprofen, probably due to its extensive protein binding (approximately 90%). Uremic patients may require a comparatively longer time to achieve the therapeutic concentration attained in normal volunteers. However, dosage adjustment is not required once a regimen is implemented in uremia.
在7名接受血液透析的尿毒症患者中研究了布洛芬的吸收和处置情况。在血液透析前1小时或4小时给每位患者口服布洛芬（400毫克）。与正常受试者相比，尿毒症患者似乎以较慢的速率吸收布洛芬。本研究中使用的血液透析系统对布洛芬的平均清除效率为16.7%，平均透析血浆清除率为22.7毫升/分钟。血液透析导致的药物回收占摄入布洛芬剂量的一小部分（不到4%）。布洛芬的半衰期（1.3 - 1.9小时）未因血液透析而显著改变。透析过程中对清除效率、药物回收和半衰期的观察表明布洛芬不可透析，这可能是由于其广泛的蛋白结合（约90%）。尿毒症患者可能需要相对更长的时间才能达到正常志愿者所达到的治疗浓度。然而，一旦在尿毒症中实施了给药方案，就不需要调整剂量。
